CliffBio
biologic

Inmazeb

atoltivimab, maftivimab, and odesivimab-ebgn

Loss of exclusivityOctober 2032projected — 12-year biologic exclusivity estimate
CompanyRegeneron Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand nameInmazeb
Active ingredientatoltivimab, maftivimab, and odesivimab-ebgn
Strength241.7MG, 241.7MG, 241.7MG/14.5ML (16.67MG, 16.67MG, 16.67MG/ML)
Dosage formInjection
RouteIntravenous
ModalityBiologic
FDA approvalOctober 2020
Marketing statusRx

More from Regeneron Pharmaceuticals

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.